SEO URLwww.firestrike.ai/deals/antengene-ucb-acquisition-2026
acquisitionAnnounced · Mar 4, 2026biotechnologySource · SpeculativeArticle · Factual
UCB acquires Antengene
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$60M
Target
Antengene
Changning, Shanghai
Acquirer
UCB
Financial Stake
Status
Announced
UCB agreed to acquire Antengene. Reported deal value: $60M. Status: Announced. Sector: biotechnology. Target headquarters context: Changning, Shanghai, China.
This page summarizes publicly available information about the transaction as of 2026-03-04. Figures and status may change as filings and press coverage update.
UCB is teaming up with Chinese biotech Antengene to develop a T cell engager in Amgen arena, alongside bubbling competition from
Deal timeline
Announced
Mar 4, 2026 · endpoints.news
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in biotechnology with a reported deal value of $60M. Figures and status may change as sources update.
Sources: endpoints.news · Primary article · FireStrike proprietary index